Wedbush analyst Yun Zhong upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the name.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYGR:
- Voyager Therapeutics selects VY1706 for program in Alzheimer’s Disease
- Voyager Therapeutics Reports Strong Q3 2024 Progress
- Voyager has sufficient resources for planned operating expenses into 2027
- Voyager Therapeutics reports Q3 EPS (16c), consensus (45c)
- VYGR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
